Can I read Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04 on EtoBox?

Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04 by Serkan Kuyumcu; Bilal Kovan; Yasemin Sanli; Fikret Buyukkaya; Duygu Has Simsek; Zeynep Gözde Özkan; Emine Goknur Isik; Meltem Ekenel; Cuneyt Turkmen is a Medicine article available to read on EtoBox.

What is Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04 about?

## Objectives: This study is set out to estimate the radiation-absorbed doses to normal organs and tumor tissue using low-dose 177lu-fapi04 dosimetry to determine the safety and theranostic potential of fibroblast activation protein-targeted radionuclide therapy. ## Patients and methods: Four patients with metastatic advanced-stage cancer were administered low-dose 177lu-fapi04 for dosimetry measurements. data acquisition for dosimetry of normal organs and tumors was performed by whole-body and 3d spect/ct imaging at 4, 24, 48, and 96 hours after administering 177lu-fapi04. blood samples were drawn at 5, 15, 30, 60, 60, 120, and 180 minutes, and at 24, 48, and 96 hours for bone marrow dosimetry calculations. ## Results: Mean absorbed doses per megabecquerel were 0.25 ± 0.16 mgy (range, 0.11-0.47 mgy), 0.11 ± 0.08 mgy (range, 0.06-0.22 mgy), and 0.04 ± 0.002 mgy (range, 0.04-0.046 mgy) for kidneys, liver, and bone marrow, respectively. the respective maximum estimated amount of radioactivity to reach radiation-absorbed dose limits were 120.9 ± 68.6 gbq, 47.5 ± 2.8 gbq, 397.8 ± 217.1 gbq, and 52.4 ± 15.3 gbq for kidneys, bone marrow, liver, and total body. the mean absorbed dose per

Who reads Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04?

Author

Serkan Kuyumcu; Bilal Kovan; Yasemin Sanli; Fikret Buyukkaya; Duygu Has Simsek; Zeynep Gözde Özkan; Emine Goknur Isik; Meltem Ekenel; Cuneyt Turkmen

Publisher

Ovid Technologies (Wolters Kluwer Health)

Published

2021

Language

EN

Field

Medicine (Health Sciences)